PCOS is now PMOS: what changed, and what didn't

If you were diagnosed with polycystic ovary syndrome, the condition you have now has a different name. As of 12 May 2026 it is Polyendocrine Metabolic Ovarian Syndrome — PMOS.

Nothing about you changed. It is worth saying that first, because a diagnosis being renamed sounds like news about your body, and it is not. It is news about a word.

What was announced, and by whom

The new name was published in The Lancet and presented at the European Congress of Endocrinology in Prague on 12 May 2026.¹⁴ The process was directed by Professor Helena Teede at Monash University, alongside Professor Terhi Piltonen and Anuja Dokras of the AE-PCOS Society and Rachel Morman of Verity, the UK patient charity, with 56 patient and professional organisations taking part.²

This was not a quick rebrand. A first attempt to rename the condition met in Sicily in October 2015 and broke up without agreement. Surveys followed in 2017, 2023 and 2025. Across all of them roughly 22,000 people were consulted — clinicians, researchers, patients and charities — with the 2025 survey alone reaching nearly 15,000.⁴

Three finalists went to a vote:

Of 90 voters, 87 backed PMOS immediately, with one more joining before the manuscript was submitted.⁴

Why “polycystic” was the wrong word

Two reasons, and the second is the one that matters clinically.

They are not cysts. What shows up on an ultrasound and gave the condition its name are immature follicles, not cystic growths. The word describes the picture inaccurately, and it frightens people who reasonably assume they have something growing inside them that needs removing.

They are not required for the diagnosis. Under the criteria in the 2023 international guideline, an adult diagnosis needs two of three features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries on ultrasound or a raised anti-Müllerian hormone level.⁵ Two of three. Which means a substantial number of women carry a diagnosis named after a feature they do not have.

Dr Lubna Pal of Yale Medicine put the deeper problem directly: the cysts “are not always present and are not the defining feature of the condition,” and the old label “has been doing a disservice. It conveys that the problem is all in the ovary.”³

That is the substantive argument for the change. This is a condition that affects insulin sensitivity, cardiovascular risk, skin, weight and mental health — the Endocrine Society describes it as hormonal fluctuations “with impacts on weight, metabolic and mental health, skin, and the reproductive system.”² A name pointing exclusively at the ovaries invites a narrower workup than the condition deserves. Pal frames the shift as moving from a microscopic view to a telescopic one.

What has not changed

Almost everything:

• Diagnostic criteria. Unchanged.
• Treatment and management guidelines. Unchanged.
• Your records. PCOS will keep appearing on medical files, insurance forms and billing codes for the foreseeable future.
• What to do next. “If you have been diagnosed with PCOS, no immediate action is required.”³

The rollout is deliberately slow: a three-year transition, with the new name fully implemented at the 2028 update of the international guideline.² If your doctor still says PCOS in 2027, nothing is wrong.

The condition itself is common — between 10% and 13% of women globally by the Rotterdam criteria,⁵ which the Endocrine Society puts at around 170 million people worldwide.²

Not everyone agreed

Worth knowing, because consensus statements can read as though dissent did not exist. Two voters objected.

Angela Grassi of the PCOS Nutrition Center questioned whether the outcome justified the effort — “all this work to change a C to an M” — and raised the cost to organisations that must now rebrand, along with the prospect of further revisions later. Sasha Ottey of PCOS Challenge objected that keeping “ovarian” in the name rules out any future recognition of the condition in men, while the changed acronym creates confusion in the meantime.⁴

Both objections are reasonable. Eighty-seven of ninety voters disagreed with them, but a reader deciding how much weight to give the change deserves to know they were made.

What to actually do with this

Two things, neither urgent.

Use the moment to widen the conversation. If your care has focused on periods and fertility, the new name is a good opening to ask your doctor about the metabolic side — blood sugar, cholesterol, cardiovascular risk.³ That question was always worth asking. It is just easier to ask now that the diagnosis says “metabolic” out loud.

Know that strength training is in the guideline. The 2023 international guideline recommends, for adults aged 18 to 64, at least 150 to 300 minutes of moderate-intensity activity or 75 to 150 minutes of vigorous activity per week, plus muscle-strengthening work on two non-consecutive days. For greater benefit and modest weight loss it raises the target to at least 250 minutes of moderate-intensity activity per week.⁵

Note what that is not. It is not a prescription to do more cardio, and it is not a phase-based template. Resistance training appears there because the condition is metabolic, and muscle is metabolically active tissue — which is precisely the logic the new name makes visible.

The honest summary

A letter changed. Underneath it, a group of clinicians spent a decade arguing that the way a condition is named shapes how it is investigated and treated, and persuaded almost everyone in the room. Whether that changes anything for you depends less on the acronym and more on whether your next appointment covers the metabolic half of a condition that was, for forty years, named after the wrong organ.

Common questions

Do I need to be re-diagnosed or re-tested now that PCOS is called PMOS?

No. The 2026 consensus changed the name, not the condition. Diagnostic criteria and treatment guidelines are unchanged, and Yale Medicine's Dr Lubna Pal states plainly that if you have been diagnosed with PCOS, no immediate action is required.

Will my doctor call it PMOS?

Not necessarily, and not yet. The change was announced in May 2026 with a three-year transition period, and full implementation is planned for the 2028 update of the international guideline. PCOS will keep appearing on medical records, insurance forms and diagnostic codes for the foreseeable future. Both names refer to the same condition.

What does PMOS stand for?

Polyendocrine Metabolic Ovarian Syndrome. Polyendocrine because more than one hormone system is involved, metabolic because insulin resistance and cardiovascular risk are central rather than incidental, and ovarian because the ovaries remain part of the picture — just not the whole of it.

Does the name change affect how I should exercise?

The recommendations did not change, but the new name makes them easier to understand. The 2023 international guideline already recommends 150 to 300 minutes of moderate or 75 to 150 minutes of vigorous activity per week, plus muscle-strengthening work on two non-consecutive days. Naming the condition metabolic makes it clearer why resistance training is in the guideline rather than an optional extra.